**CURRICULUM VITAE** (March, 2024)

**NAME:** John Wesson Ashford, Jr., M.D., Ph.D. (Wes)

**Current Positions:**

Clinical Professor (affiliated), Department of Psychiatry and Behavioral Science, Stanford

Staff Psychiatrist, VA Palo Alto Health Care System

Senior Research Scientist, Stanford / VA Aging Clinical Research and Alzheimer Centers

Director, War Related Illness and Injury Study Center, VA Palo Alto Health Care System

**MARITAL STATUS:** Married, 4 children, 8 grandchildren

**RESIDENCE:** Redwood City, California 94061

**PROFESSIONAL ADDRESS:**

War Related Illness & Injury Study Center

VA Palo Alto Health Care System

3801 Miranda Way - 151Y

Palo Alto, CA 94304-1207

Tel: (650) 493-5000 (VA Palo Alto HCS, War Related Illness & Injury Study Center)

Fax: (650) 852-3297

Academic e-mail: [ashford@stanford.edu](mailto:ashford@stanford.edu)

VA email: [wes.ashford@va.gov](mailto:wes.ashford@va.gov)

Business e-mail: [washford@medafile.com](mailto:washford@medafile.com)

Personal e-mail: [wes.ashford@gmail.com](mailto:wes.ashford@gmail.com)

**UNDERGRADUATE EDUCATION**

1966 - 1967 Cornell University, Ithaca, New York

1967 - 1970 University of California, Berkeley, B.A. June, 1970

**MEDICAL EDUCATION**

1970 - 1974 University of California, Los Angeles, M.D. September, 1974

**GRADUATE EDUCATION**

1970 - 1984 University of California, Los Angeles - Neuroscience

1971 Summer Fellowship in sleep research (Dr. M. Jouvet, Lyon, France)

1974 Teaching Assistant, Basic Neurology for Medical students (Dr. J. Schlag)

1975 Teaching Assistant, Neuroanatomy, Neurophysiology

for graduate students (Drs. Scheibel, Decima)

1975 Advanced to Candidacy - Neuroscience

1975 - 1980 On leave of absence for Psychiatric Residency

1979 - 1984 Laboratory of Dr. J. M. Fuster (Doctoral Committee Chairman)

Dissertation signed in March, 1984

June, 1984 Ph.D. awarded in Neuroscience

**POSTGRADUATE TRAINING**

1975 - 1976 Rotating Psychiatry Internship, UCLA

1976 - 1979 Residency in Psychiatry, UCLA

1978 - 1979 Chief Resident, Geriatric Neuropsychiatry Inpatient Unit, UCLA

1977 - 1979 Resident, Co-founder, UCLA Neurobehavior Clinic

1979 - 1980 Fellowship in Psychiatry, UCLA

1980 - 1981 Fellowship, Mental Health Training Program, UCLA

**LICENSURES**

1976 – 1986, 2005 - present California State Medical License

1976 - present DEA License

1981 Diplomate, American Board of Psychiatry and Neurology (Psychiatry)

1985 - 1992 Illinois State Medical License

1992 - present Kentucky State Medical License

**MEMBERSHIPS**

**Active or Retired**

American Association for Geriatric Psychiatry

(Program Committee, 2001, 2002, 2003)

(CME committee, 2002, 2003, 2004, 2005, 2006)

International Psychogeriatrics Association

(Program Committee, Membership Committee, 2002, 2003)

American Psychiatric Association

Northern California Psychiatry Society

Society for Brain Mapping and Therapeutics

(President, 2016 – 2017)

Society for Neuroscience

(President, Sangamon Chapter, Springfield, Illinois, 1991)

**Past**

American Association for the Advancement of Science

Southern Association for Research in Psychiatry

(Secretary, 1997-1998; organizer of 1998 meeting)

American Medical Association

Gerontological Society of America

International Neuropsychological Society

**EDITORIAL BOARD**

Journal of Mental Health and Aging (2003-2005)

Clinical Editor, Senior Editor, Journal of Alzheimer’s Disease (2008 – 2012; 2012- present),

**JOURNAL REVIEWER** (sample from over 30)

Alzheimer’s Disease and Associated Disorders

Alzheimer’s & Dementia

Archives of General Psychiatry

American Journal of Geriatric Psychiatry

JAMA

Journal of Alzheimer’s Disease (Senior Editor)

Life Sciences

Neurology

**GRANT/AWARD REVIEWER**

NIH Population Sciences and Epidemiology Panel (2013)

NIH Panels (various Alzheimer related) (2013-present)

NIH SBIR (Small Business Innovation Research) Panel (2009 – present)

Alzheimer Association grant applications (2001- present)

State of California, Alzheimer grant applications (2004 - 2008)

VA Office of Research and Development (various, 2013-present)

CDMRP (Department of Defense, Congressionally Directed Medical Research Program (2015 – present, twice as committee chair)

**PROFESSIONAL APPOINTMENTS**

07/79 - 09/79 Staff Psychiatrist, Atascadero State Hospital

10/79 - 06/80 Associate Director, Geriatric Neuropsychiatry Inpatient Unit, UCLA/NPI

07/80 - 06/85 Director, Geriatric Psychiatry Outpatient Clinic, UCLA/NPI (50% time)

08/84 - 06/85 Research Director, Geriatric Psychiatry Ward, Brentwood VA Hospital (50% time)

09/85 - 12/90 Consultant, Geriatric Psychiatry, Adolf Meyer State Mental Hospital, Illinois

01/91 - 12/92 Staff Psychiatrist, VAMC, Martinez, California

12/92 - 03/03 Staff Psychiatrist, VAMC, Lexington, Kentucky

10/94 - 03/03 Director, Memory Disorders Clinic, VAMC, Lexington

07/00 - 9/01 Acting Chief, Mental Health Service, VAMC, Lexington

03/03 – pres. Staff Psychiatrist, Palo Alto VA Health Care System, Palo Alto, CA

07/07 – pres. Director, War Related Illness and Injury Study Center,

VA Palo Alto Health Care System, Palo Alto, CA

**ACADEMIC APPOINTMENTS**

07/83 - 06/85 Adjunct Lecturer, Department of Psychiatry, UCLA

07/85 - 12/90 Assistant Professor, Department of Psychiatry, Southern Illinois University (Springfield)

01/91 - 12/92 Associate Professor, Department of Psychiatry, University of California, Davis

12/92 - 06/03 Associate Professor, Departments of Psychiatry and

Neurology and Sanders Brown Center on Aging, University of Kentucky

06/95 Tenure Granted

12/92 - 6/01 Vice-chair of Research, Department of Psychiatry, University of Kentucky

03/03 - pres. Senior Research Scientist, Stanford / VA Aging Clinical Research Center

03/05 – 09/09 Associate Professor, Stanford University Department of Psychiatry (abeyed)

09/09 - pres. Clinical Professor (affiliated), Department of Psychiatry and Behavioral Sciences,

School of Medicine, Stanford University

**Committee Memberships**

10/09 – pres. Stanford University – Internal Review Board (IRB)

2003 – 2010. VA Palo Alto Health Care System – Medication Management Committee

2007 – 2011. VA Palo Alto Health Care System –Informatics Committee

Stanford University, Department of Psychiatry & Behavioral Sciences –

2005 – pres. Psychiatry Residency Selection Committee

2011 – 2015 Appointment & Promotions Committee – Clinician Educator Faculty Line

**HONORS**

05/85 Finalist, Lindsley Prize (Best Dissertation in Behavioral Neuroscience), Soc. for Neuroscience

06/90 Teacher of the Year, Southern Illinois University Psychiatry Residency

11/93 Clinical Digest Series--Outstanding Article

(Coburn, K.L. Ashford, J.W., and Moreno, M.A., 1993--see publication #31)

03/04-2013 Scientific Advisory Board, Northern California Alzheimer Association

08/06- pres. Chair, Memory Screening Advisory Board, Alzheimer’s Foundation of America

2008 - pres. Medical Advisory Board, Alzheimer’s Foundation of America, Chair – 2018

2017 Golden Axon Award, Society for Brain Mapping & Therapeutics

**RESEARCH AWARDS (ACTIVE)**

Collaborator with the Stanford / VA Alzheimer Center, supporting role and Principle Local

Investigator roles in several on-going and developing projects, including several studies of the

NIA funded Alzheimer’s Disease Cooperative Study group and the Alzheimer’s Disease

Neuroimaging Initiative.

**RESEARCH AWARDS (PAST)**

**Principal Investigator**

11/84 - 06/85 NPI/UCLA Biomedical Research Support Grant: "Influence of Transdermal

Nicotine on Memory Performance in Alzheimer's Type Dementia." ($5,000)

08/87 - 12/89 Southern Illinois University Coordinator (5% time): National Institute of Aging

1U01AG06777-01); Alzheimer’s Disease Patient Registry (P.I. J. Brody, University of Illinois,

Chicago), $27,525. (revised 5U01AG006777-02, 9/30/86 - 12/31/89 to Dr. Brody and

5U01AG006777-03, 9/30/86 - 12/31/90 to Dr. Donna Cohen).

12/87 - 1/91 R.J. Reynolds Tobacco Company, Inc., "Effect of nicotine on cholinergic

receptors in the brain and on behavior in the monkey": $50,000

01/94 - 06/96 Miles Laboratories: "Study of Metrifonate" Phase II-b (D93-029),$230,000; 20% time

05/94 - 12/96 Miles Laboratories: "Study of Metrifonate" Phase II-bx(D93-029x),$100,000; 10% time

01/94 - 1997 "Haloperidol, Trazodone, and Behavior Management Techniques in Alzheimer's Disease Patients with Disruptive Agitated Behaviors: A Controlled Clinical Trial." Sub-contract from the Alzheimer's Disease Cooperative Studies Group, Leon Thal, P.I., University of California, San Diego, Funded by National Institute of Aging, $63,000; 10% time

07/94 - 6/95 "Wolfe County Alzheimer's Study", Research Development Review Committee, Department of Psychiatry and State Department of Mental Health, $10,000; 5% time

1994 - 1998 Bayer Pharmaceutical: Safety and Efficacy of Metrifonate in Alzheimer Patients

01/96 - 2001 Progressive Deterioration of Cortical Blood Flow by Localized Anatomical Element (LOXEL) Across the Full Spectrum of Deterioration in Alzheimer's Disease. DuPont Pharmaceutical (gift of ECD, Ethylene Cysteinate Dimer)

11/98 - 2002 Olanzapine vs. risperidone and placebo in the treatment of psychosis and associated behavioral disturbances in patients with dementia (funded by Eli Lilly Pharmaceuticals, managed by SCIREX Corp., $107,798)

11/98 - 2002 A randomized evaluation-blind study of olanzapine and valproic acid in the treatment of agitation in Alzheimer's patients (investigator initiated project, funded by Eli Lilly Pharmaceuticals, $160,000, 30 patients, not completed).

Principal Investigator (2002) Lithium treatment of Alzheimer's disease: Effect on CSF TAU (cerebro-spinal fluid - microtubule associated protein - tau), acute and chronic treatment ($400,000 - GCRC - General Clinical Research Center, component project)

Principal Investigator (7/1/2002 - 6/30/2003) Inhibition of Alzheimer neuropathology with lithium. University of Kentucky, College of Medicine ($15,000)

Principal Investigator(s): John Wesson Ashford, MD, PhD, Nikolaos Tezapsidis (contact), PHD

Project Title: Leptin as a Therapy for Alzheimer's Disease, Grant Number: 2R44AG029670-03

Project Period: 04/03/2006 – 07/31/2012

Principal Investigator: John Wesson Ashford, MD, PhD. Project Title: rTMS for the Treatment of Chronic Pain in GW1 Veterans. VA Merit Award. Award Document Number: ICX000792A. Project Period: 11/01/2011-10/31/2015.

**Co-Investigator**

04/84 - 08/89 NIH; "Emission Computed Tomography of Local Cerebral Functions"; (P.I.: D. Kuhl); $2,000,000: 15% time.

02/87 - 06/89 NIH; "Effects of Long Acting Anticholinesterases in Alzheimer's Disease"; (1 RO1 MKH 41821); (P.I.: R. E. Becker), $91,752: 10% time.

07/86 - 06/89 NIMH; "Clinical Training in Geriatric Mental Health"; (5 T24 MH 18449); (P.I.: V. Kumar), $211,537: 10% time.

10/87 - 06/88 Illinois Department of Public Health; "Human Chromosome 21-beta amyloid and D-21 S11 Genes in Familial and Non-Familial Alzheimer's Disease"; (P.I.: L. Maroun), $20,000: 5% time.

10/87 - 06/88 Illinois Department of Public Health; "Alzheimer's Disease-like Changes in a Hippocampal Cell Culture Model"; (P.I.: G. Brewer), $20,000: 5% time.

02/87 - 12/90 Illinois Department of Public Health; "Southern Illinois University School of Medicine's Regional Alzheimer's Disease Assistance Center"; (P.I.: R. Robertson), $3,100,000: 30% time.

1/93 - 4/94 Miles Laboratories: "Study of Metrifonate"; (P.I.: Pettigrew), 10% time

10/93 - 09/96 Geriatric Education Center Grant - NIA, $805,727; (P.I. Markesbery) 5% time

07/93 - 2002 Sub-contract from the Alzheimer's Disease Cooperative Study Group, Leon Thal, P.I., University of California, San Diego, Funded by National Institute of Aging,(Site P.I.: Schmitt)

1) Instrument Protocol.

2) Study of melatonin in Alzheimer's disease

3) Study of estrogen in Alzheimer's disease

4) Treatment of mild cognitive impairment

05/95 - 04/00 Alzheimer's Disease Research Center Clinical Core-NIA,$1,4 mil.;(P.I.: Markesbery - 10% time

1997 - 2000 Study of Ondansetron, Quintiles (P.I. Schmitt)

1998 - 2001 Study of memantine, MERZ (P.I. Schmitt)

2003 – present – numerous at VA Palo Alto HCS and Stanford University

**DISSERTATION**

1984 Ashford, J.W. Electrophysiology of visual encoding in the monkey. PhD Dissertation, Department of Neuroscience, UCLA, Chairman: J. Fuster.

**PUBLICATIONS** (peer-reviewed journals)

List of Published Work in MyBibliography: (over 185 references)

<https://www.ncbi.nlm.nih.gov/sites/myncbi/john.ashford.1/bibliography/48071896/public/?sort=date&direction=descending>

1. 1972 Pascalon, A., Ashford, W., Dansereau, J. and Mouret, J. The effect of 6-Chlorotryptophan on sleep in the rat. Life Sciences. 11:893-903, Part 1.

2. 1979 Ashford, J.W. and Ford, C.V. Use of MAO inhibitors in elderly patients. American Journal of Psychiatry, 136:1466-1467.

3. 1980 Ashford, J.W., Schulz, S.C. and Walsh, G.O. Violent automatism in a partial complex seizure. Archives of Neurology, 37:120-122.

4. 1981 Ashford, J.W., Soldinger, S., Schaeffer, J. Cochran, L. and Jarvik, L.F. Physostigmine and its effect on six patients with dementia. American Journal of Psychiatry, 138:829-830.

5. 1982 Fuster, J.M., Willey, T.J., Riley, D.M. and Ashford, J.W. Effects of ethanol on visual evoked responses in monkeys performing a memory task. Electroencephalography and Clinical Neurophysiology, 53:621-633.

6. 1985 Ashford, J.W., Coburn, K.L. and Fuster, J.M. The elgiloy microelectrode: fabrication techniques and characteristics. Journal of Neuroscience Methods. 14:247-252.

7. 1985 Ashford, J.W. and Fuster, J.M. Occipital and inferotemporal responses to visual signals in the monkey. Experimental neurology. 90:444-466.

8. 1985 Ashford, J.W. and Jarvik, K.L. Alzheimer's disease: does neuron plasticity predispose to axonal neurofibrillary degeneration? New England Journal of Medicine. 5:388-389.

9. 1987 Ashford, J.W., Rosenblatt, M.J., Bekian, C. and Hayes, T. The complete dementia evaluation: complications and complexities. The American Journal of Alzheimer's Care and Research. 9-15.

10. 1988 Coburn, K.L., Ashford, J.W. and Moreno, M.A. Electrocortical mapping in a mixed AD-CVA patient. Brain Atlas Special Interest Society Newsletter, Touching Basis, 2:6-11.

11. 1988 Kumar, V., Smith, R.C., Sherman, K.A., Ashford, W., Murphy, J., Giacobini, E. and Colliver, J. Cortisol responses to cholinergic drugs in Alzheimer's disease. International Journal of Clinical Pharmacology Therapy and Toxicology. 26:471-476.

12. 1988 Small, G.W., Kuhl, D.E., Fujikawa, D.G. and Ashford, J.W. Clinical characterization of Alzheimer's disease: reliability of "age at onset" and a new descriptor, "age at shift". Journal of Geriatric Psychiatry and Neurology. 1:207-211.

13. 1989 Small, G.W., Kuhl, D.E., Riege, W.H., Fujikawa, D.G., Ashford, J.W., Metter, E.J. and Mazziotta, J.C. Cerebral glucose metabolic patterns in Alzheimer's disease. Archives of General Psychiatry. 46:527-532.

14. 1989 Parks, R.W., Crockett, D.J., Tuokko, H., Beattie, B.L., Ashford, J.W., Coburn, K.L., Zec, R.F., Becker, R.E., McGeer, P.L. and McGeer, E.G. Neuropsychological "systems efficiency" and positron emission tomography. Journal of Neuropsychiatry. 1:269-282.

15. 1989 Ashford, J.W., Kolm, P., Colliver, J.A., Bekian, C. and Hsu, L.N. Alzheimer patient evaluation and the mini-mental state: item characteristic curve analysis. Journal of Gerontology. 44:139-146

16. 1989 Ashford, J.W., Sherman, K.A. and Kumar, V. Advances in Alzheimer therapy: cholinesterase inhibitors. Neurobiology of Aging, 10:99-105.

17. 1990 Coburn, K.L., Ashford, J.W. and Fuster, J.M. Visual response latencies in temporal lobe structures as a function of stimulus information load. Behavioral Neuroscience 104:62-73.

18. 1990 Cohen, D., Paveza, G., Levy, P.S., Ashford, J.W., Brody, J.A., Eisdorfer, C., Gorelick, P., Hirschman, R., Luchins, D., Trozzolo, T. and Shaw, H. An Alzheimer's disease patient registry: the prototype Alzheimer collaborative team (PACT). Aging 2:312-316.

19. 1990 Cohen, D., Luchins, D., Eisdorfer, C., Paveza, G., Ashford, J.W. Gorelick, P., Hirschman, R., Freels, S., Levy, P., Semla, T. and Shaw H. Caring for relatives with Alzheimer's disease: The mental health risks to spouses, adult children, and other family caregivers. Behavior, Health and Aging 1:171-182.

20. 1991 Parks, R.W., Coburn, K.L., Zec, R.F., Ashford, J.W., Crockett, D.J., Kuhn, M., Moreno, M.A., Rashid, A., Vicari, S. and Feldman, E. Electrocortical mapping, MRI, and neuropsychological measures: evidence of Alzheimer's disease in the presence of vascular lesions. Archives of Clinical Neuropsychology 6:393-408.

21. 1991 Coburn, K.L., Ashford, J.W. and Moreno, M.A. Visual evoked potentials in dementia: selective delay of flash P2 in probable Alzheimer disease. Journal of Neuropsychiatry and Clinical Neuroscience 3:431-435.

22. 1992 Hargrave, R. and Ashford, J.W. The use of MAO inhibitors in a patient with atypical depression and Parkinson's Disease. American Journal of Psychiatry. 149:1751-1752.

23. 1992 Ashford, J.W., Kumar, V., Barringer, M., Becker, M., Bice, J., Ryan, N. and Vicari, S. Assessing Alzheimer severity with a global clinical scale. International Psychogeriatrics 4:55-74.

24. 1992 Eisdorfer, C., Cohen, D., Paveza, G.J., Ashford, J.W., Luchins, D.J., Gorelick, P.B., Hirschman, R.S., Freels, S.A., Levy, P.S., Semla, T.P, and Shaw, H.A. An empirical evaluation of the global deterioration scale for staging Alzheimer's disease. American Journal of Psychiatry 149:190-194.

25. 1992 Paveza, G.J., Cohen, D., Eisdorfer, C., Freels, S., Semla, T., Ashford, J.W., Gorelick, P., Hirschman, R., Luchins, D. and Levy, P. Severe family violence and Alzheimer's disease: Prevalence and risk factors. The Gerontologist 32:493-497.

26. 199 Luchins, D.J., Hanrahan, P., Cohen, D., Eisdorfer, C., Paveza, G., Ashford, J.W., Gorelick, P., Hirschman, R., Freels, S., Levy, P., Shaw, H. Are there clinical differences between familial and non-familial Alzheimer's disease? American Journal of Psychiatry 149:1023-1027.

27. 1992 Brewer, G.J. and Ashford, J.W. Elderly human serum stimulates Alzheimer markers in cultured hippocampal neurons. Journal of Neuroscience Research 33:355-369.

28. 1992 Freels, S., Cohen, D., Eisdorfer, C., Paveza, G., Gorelick, P., Luchins, D.J., Hirschman, R., Ashford, J.W., Levy, P., Semla, T., and Shaw, H. Functional status and clinical findings in patients with Alzheimer's Disease. Journal of Gerontology 47(6):M177-M182.

29. 1993 Cohen, D., Eisdorfer, C., Gorelick, P., Paveza, G., Luchins, D.J., Freels, S., Ashford, J.W., Semla, T., Levy, P., Hirschman, R. Psychopathology associated with Alzheimer's disease and related disorders. Journal of Gerontology: Medical Sciences 48(6):M255-M260.

30. 1993 Cohen, D., Eisdorfer, C., Gorelick, P., Luchins, D., Freels, S., Semla, T., Paveza, G., Shaw, H., Ashford, J.W. Sex differences in the psychiatric manifestations of Alzheimer's disease. Journal of the American Geriatric Society 41(3):229-232.

31. 1993 Coburn, K.L., Ashford, J.W. and Moreno, M.A. Delayed late-components of visual global field-power in probable Alzheimer disease. Journal of Geriatric Psychiatry and Neurology 6:72-77.

32. 1993 Semla, T.P., Cohen, D., Paveza, G., Eisdorfer, C., Gorelick, P., Luchins, D., Hirshman, R., Freels, S., Levy, P., Ashford, J.W. Drug use patterns in persons with Alzheimer's disease and related disorders living in the community. Journal of the American Geriatric Society 41:408-413.

33. 1994 Ashford, J.W.: Meeting Report of: "Challenging Views of Alzheimer's disease", Cincinnati, Ohio, July 27-29, 2001. In: Expert Reviews in Neurotherapeutics, 1:7-10.

34. 1994 Coburn, K.L., Ashford, J.W., & Moreno, M.A. Delayed late component of visual global field power in probable Alzheimer's disease. Parkinson/Alzheimer Digest, 5:23-24

35. 1995 Smith, C.J., Lippiello, P.M. and Ashford, J.W. Smoking, Alzheimer's disease, and confounding with genes. Lancet, 345:1054.

36. 1995 Ashford, J.W., Shan, M., Butler, S., Rajesekar, A. & Schmitt, F. "Temporal Quantification of Alzheimer's Disease Severity: 'Time Index" Model.'" Dementia, 6(5):269-280.

37. 1995 Semla, T.P., Cohen, D., Freels, S., Paveza, G., Ashford, J.W., Gorelick, P., Luchins, D., & Eisdorfer, C. Psychotropic drug use in relation to psychiatric symptoms in community-living persons with Alzheimer's disease. Pharmacotherapy, 15(4):495-501.

38. 1995 Mark, R.J., Ashford, J.W., Goodman, Y., and Mattson, M. P. Anticonvulsants Attenuate Amyloid ?-Peptide Neurotoxicity, Ca2+ Deregulation, and Cytoskeletal Pathology. Neurobiology of Aging, 16(2):187-198.

39. 1995 Semla, T.P., Cohen, D.C., Freels, S., Paveza, G.J., Ashford, J.W., et. al. Psychotropic Drug Use in Relation to Psychiatric Symptoms in Community-Living Persons With Alzheimer's Disease. Pharmacotherapy, 15(4):495-501.

40. 1996 Freels, S. Cohen, D. Semla, T. Paveza, G. Eisdorfer, C. Luchins, D. Ashford, J. W. Gorelick, P. Shaw, H. Levy, P. Predicting Survival in Patients With Alzheimer's Disease Living in the Community. Journal of Mental Health and Aging, 2(2):115-124.

41. 1996 Butler, M., Ashford, J.W., and Snowdon, D.A. Age, Education, and Changes in the Mini-Mental State Exam Scores of Elderly Women. Journal of American Geratrics Society, 44:675-681.

42. 1996 Ashford, J.W., Schmitt, Frederick A. and Kumar, Vinod. Diagnosis of Alzheimer's Disease. Psychiaric Annals, 26(5):262-268.

43. 1996 Ashford, J.W., and Miller, T.W. Effect of Trazodone on Sleep in PTSD Patients." Journal of Contemporary Psychotherapy, 26(3):221-233.

44. 1997 Geddes, J.W., Tekirian, T.L., Soultanian, N.S., Ashford, J.W., Davis, D. G., and Markesbery, W.R. Comparison of Neuropathologic Criteria for the Diagnosis of Alzheimer's Disease. Neurobiology of Aging, 18(S4):S99-S105.

45. 1997 Sano, M., et. al. (Ashford, J. W., member of the Alzheimer's Disease Cooperative Study) A Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's Disease. The New England Journal of Medicine, 38(17):1216-1247.

46. 1997 Schmitt, F.A., Ashford, W., Ernesto, C., Saxton, J., Schneider, L.S., Clark, C.M., Ferris, S.H., Mackell, J.A., Schafer, K., Thal, L.J., and the Alzheimer's Disease Cooperative Study. The Severe Impairment Battery: Concurrent Validity and the Assessment of Longitudinal Change in Alzheimer's Disease. Alzheimer Disease and Associated Disorders. 11(2):S51-S56.

47. 1998 Pettigrew, L.C., Bieber, F., Lettieri, J., Wermeling, D.P., Schmitt, F.A., Tikhtman, A.J., Ashford, J.W., Smith, C.D., Wekstein, D.R., Markesbery, W.R., Orazem, J., Ruzicka, B.B., Mas, J., and Gulanski, B. A Study of the Pharmacokinetics, Pharmacodynamics and Safety of Metrifonate in Alzheimer's Disease Patients. Journal of Clinical Pharmacology. 38:236-245.

48. 1998 Piecoro, L.T., Wermeling, D.P., Schmitt, F.A., Ashford, J.W. Seizures in patients receiving concommitant antimuscarinics and acetylcholinesterase inhibitor. Pharmacotherapy. 18:1129-1132.

49. 1998 Ashford, J.W., Soultanian, N.S., Zhang, S.-X., Geddes, J.W. Neuropil threads are colinear with MAP2 immunostaining in neuronal dendrites of Alzheimer brain. Journal of Neuropathology and Experimental Neurology. 57:972-978.

50. 1998 Shih, W.-J., Davis, D.G., Stipp, V., Ashford, W., Magoun, S. Bilateral perfusion defect/hypoperfusion in temporal and parietal regions on brain SPECT. Seminars in Nuclear Medicine. 28:192-193.

51. 1998 Cummings, J.L., et al. (Ashford, J.W., member of metrifonate study group). Metrifonate treatment of the cognitive deficits of Alzheimer's disease. Neurology. 50:1214-1221.

52. 1999 Shih, W.-J., Ashford, J.W., Stipp, V., Magoun, S.L. Coupal, J.J., Gross, K.K. Consecutive brain SPECT surface three-dimensional displays show progression of cerebral cortical abnormalities in Alzheimer's disease. Clinical Nuclear Medicine. 24:773-777.

53. 2000 Ashford, J.W., Shih, W.-J., Coupal, J., Shetty, R., Schneider, A., Cool, C., Aleem, A., Stipp, V., Mendiondo, M.S., Schmitt, F.A. Single SPECT measures of cerebral cortical perfusion reflect "Time-Index" estimation of dementia severity in Alzheimer's disease. Journal of Nuclear Medicine. 41:57-64

54. 2000 Mediondo, M.S., Ashford, J.W., Kryscio, R.J., Schmitt, F.A. Modeling mini-mental state exam changes in Alzheimer's disease. Statistics in Medicine. 19:1607-1616.

55. 2000 Mulnard, R.A., et al for the Alzheimer's Disease Cooperative Study (Ashford, J.W., listed). Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: A randomized controlled trial. JAMA. 283:1007-1015.

56. 2000 Schmitt, F.A., Davis, D.G., Wekstein D.R., Smith, C.D., Ashford, J.W., Markesbery, W.R. "Preclinical" AD revisited: Neuropathology of cognitively normal older adults. Neurology. 55:370-376.

57. 2000 Shih, W.-J., Ashford, W., Davis, D.G., Stipp, V., Magoun, S. Bilateral perfusion defect/hypoperfusion in temporal and parietal regions on brain SPECT. Seminars in Nuclear Medicine. 28:192-193.

58. 2001 Ashford, J.W., Schmitt, F.A. Modeling the time-course of Alzheimer dementia. Current Psychiatry Reports, 3:20-28.

59. 2002 Ashford, J.W., Mortimer, J.A. Non-familial Alzheimer's disease is mainly due to genetic factors. Journal of Alzheimer's Disease. 4:1-9.

60. 2002 Ashford, J.W. ApoE4: Is it the absence of good or the presence of bad? Journal of Alzheimer's Disease. 4:141-3

61. 2002 Schmitt, F.A., Cragar, D., Ashford, J.W., Reisberg, B, Ferris, S., Mobius, H.-J., Stoffler, A. Measuring cognition in advanced Alzheimer's disease for clinical trials. Journal of Neural Transmission [Suppl]. 62:135-148.

62. 2002 Teter, B., Ashford, J.W. Neuroplasticity in Alzheimer's Disease. Journal of Neuroscience Research. 70:402-437.

63. 2003 Goldstein L, Ashford JW, Busciglio J, Crutcher K, Gouras G, Kinoshita J, Mandelkow E, Sudol M. From here to there: AbetaPP as an axonal transport receptor--how could this explain neurodegeneration in AD. J Alzheimers Dis 5:483-9.

64. 2003 Mendiondo, M.S, Ashford, J.W., Kryscio R.J., Schmitt, F.A. Designing a Brief Alzheimer Screen (BAS). J Alzheimers Dis. 2003 Oct;5(5):391-8.

65. 2004 Yesavage, J.A., Sheikh, J., Noda, A., Murphy, G., O'Hara, R., Hierholzer, R., Battista, M., Ashford, J.W., Kraemer, H.C., Tinklenberg, J. Use of a VA pharmacy database to screen for areas at high risk for disease: Parkinson's disease and exposure to pesticides. Journal of Geriatric Psychiatry Neurology. 17(1):36-8.

66. 2004 Ashford, J.W. APOE Genotype effects on Alzheimer’s disease onset and epidemiology. Journal of Molecular Neuroscience. 23(3) :155-163.

67. 2004 Raber, J., Huang, Y., Ashford, J.W. ApoE genotype accounts for the vast majority of AD risk and AD pathology. Neurobiology of Aging 25(5):641-50.

68. 2005 Ashford JW, Atwood CS, Blass JP, Bowen RL, Finch CE, Iqbal K, Joseph JA, Perry G. What is aging? What is its role in Alzheimer's disease? What can we do about it? J Alz Dis 7(3):247-53; discussion 255-62.

69. 2006 Yesavage JA, Sheikh J, Noda A, Murphy G, O'hara R, Hierholzer R, Battista M, Ashford JW, Schneider B, Hoblyn J, Kraemer HC, Tinklenberg J. Spatial test for agricultural pesticide "blow-in" effect on prevalence of Parkinson's disease. Journal of Geriatric Psychiatry & Neurology 19(1):32-5.

70. 2006 Ashford, J.W., Borson, S., O’Hara R, Dash P, Frank L, Robert P, Shankle WR, Tierney MC, Brodaty H, Schmitt FA, Kraemer HC, Buschke H. Should older adults be screened for dementia? Alzheimer’s & Dementia. 2(April): 76-85.

71. 2006 Noda A, Kraemer HC, Taylor JL, Schneider B, Ashford JW, Yesavage JA. Strategies to reduce site differences in multisite studies: a case study of Alzheimer disease progression. Am J Geriatr Psychiatry 14:931-8.

72. 2006 Ota KS, Friedman L, Ashford JW, Hernandez B, Penner AL, Stepp AM, Raam R, Yesavage JA. The Cost-Time Index: A new method for measuring the efficiencies of recruitment-resources in clinical trials. Contemp Clin Trials. 27L494-7.

73. 2006 Schmitt FA, Mendiondo MS, Kryscio RJ, Ashford JW. A brief Alzheimer’s screen for clinical practice. Research Practice in Alzeimer’s Disease 11:1-4.

74. 2007 Ashford JW, Borson S, O’Hara R, Dash P, Frank L, Robert P, Shankle WR, Tierney MC, Brodaty H, Schmitt FA, Kraemer HC, Buschke H, Fillit H. Should older adults be screened for dementia? Screening for evidence of dementia is important! Alzheimer's and Dementia April;3:75-80..

75. 2007 Ashford JW, Kraemer HC, Tinklenberg JR, O’Hara R, Taylor JL, Yesavage JA. Statistical and pharmacoeconomic issues for dementia screening. Alzheimer's & Dementia April;3:126.

76. 2007 Tinklenberg JR, Kraemer HC, Yaffe K, Ross L, Sheikh J, Ashford JW, Yesavage JA, Taylor JL. Donepezil treatment and Alzheimer disease: can the results of randomized clinical trials be applied to Alzheimer disease patients in clinical practice? American Journal of Geriatric Psychiatry. Nov;15(11):953-60.

77. 2008 Ashford JW, Borson S. Primary care screening for dementia and mild cognitive impairment. JAMA. Mar 12;299(10):1132-3.

78. 2008 Miller JL, Ashford JW, Archer SM, Rudy AC, Wermeling DP. Comparison of intranasal administration of haloperidol with intravenous and intramuscular administration: a pilot pharmacokinetic study. Pharmacotherapy. Jul;28(7):875-82.

79. 2008 Ashford JW. Screening for Memory Disorder, Dementia, and Alzheimer's disease. Aging Health. 4(4):399-432

80. 2008 Greco SJ, Sarkar S, Johnston JM, Zhu X, Su B, Smith MA, Casadesus G, Ashford JW, Tezapsidis N. Leptin reduces Alzheimer’s disease-related tau phosphorylation in 3 neuronal cells. Biochemical and Biophysical Research Communications. Nov 21;376(3):536-41.

81. 2008 Ashford JW. Integration of EEG and brain imaging: advancing the understanding of neuro-cognitive dysfunction. J Alzheimers Dis. Nov;15(3):373-4.

82. 2008 Yesavage JA, Friedman L, Ashford JW, Kraemer HC, Mumenthaler MS, Noda A, Hoblyn J. Acetylcholinesterase inhibitor in combination with cognitive training in older adults. J Gerontol B Psychol Sci Soc Sci. Sep;63(5):P288-94.

83. 2009 Tezapsidis N, Smith MA, Ashford JW. Central obesity and increased risk of dementia more than three decades later. Neurology. 2009 Mar 17;72(11):1030-1.

84. 2009 Tezapsidis N, Johnston JM, Smith MA, Ashford JW, Casadesus G, Robakis NK, Wolozin B, Perry G, Zhu X, Greco SK, Sarkar S. Leptin: A novel therapeutic strategy for Alzheimer’s disease. Journal of Alzheimer’s Disease. 16:1-10.

85. 2009 Greco SJ, Sarkar S, Casadesus G, Zhu X, Smith MA, Ashford JW, Johnston JM, Tezapsidis N. Leptin inhibits glycogen synthase kinase-3beta to prevent tau phosphorylation in neuronal cells. Neuroscience Letters May 22;455(3):191-4.

86. 2009 Rosen A, Zhang Y, Zhan W, Kasprisin A, Martinson S, Cheng J, Weiner M, Yesavage JA, Ashford JW. Case 41. Arcuate fasciculus damage seen on DTI in a blast-exposed soldier with mild traumatic brain injury (mTBI) with associated conduction aphasia. Military Medicine, Radiology Corner Nov; 174(11):v-vi.

87. 2009 Halbauer J, Ashford JW, Zeitzer JM, Adamson, MM, Lew HL, Yesavage JA. Neuropsychiatric diagnosis and management of chronic sequelae of war-related mild to moderate traumatic brain injury. Journal of Rehabilitation Research & Development. 46(6):757-796.

88. 2010 Adamson MM, Landy KM, Duong S, Fox-Bosetti S, Ashford JW, Murphy GM, Weiner M, Taylor JL. Apolipoprotein E varepsilon4 influences on episodic recall and brain structures in aging pilots. Neurobiol Aging. Jun;31(6):1059-63.

89. 2010 Greco SJ, Bryan KJ, Sarkar S, Zhu X, Smith MA, Ashford JW, Johnston JM, Tezapsidis N, Casadesus G. Leptin reduces pathology and improves memory in a transgenic mouse model of Alzheimer's disease. J Alzheimers Disease, 19(4):1155-67.

90. 2011 Ashford JW, Gere E, Bayley PJ. Measuring Memory in Large Group Settings Using a Continuous Recognition Test. J Alzheimers Dis. 2011 Sep 9. 27(4):885-95.

91. 2011 Greco SJ, Hamzelou A, Johnston JM, Smith MA, Ashford JW, Tezapsidis N. Leptin boosts cellular metabolism by activating AMPK and the sirtuins to reduce tau phosphorylation and β-amyloid in neurons. Biochem Biophys Res Commun. 414(1):170-174

92. 2011 Ashford JW, Salehi A, Furst A, Bayley P, Frisoni GB, Jack CR Jr, Sabri O, Adamson MM, Coburn KL, Olichney J, Schuff N, Spielman D, Edland SD, Black S, Rosen A, Kennedy D, Weiner M, Perry G. Imaging the Alzheimer Brain. J Alzheimer’s Disease. 26(Sup 3):1-27.

93. 2011 Ashford JW, Coburn KL, Rose TL, Bayley PJ. The topography of P300 energy loss in aging and Alzheimer’s disease. Journal of Alzheimer’s Disease. 26(Sup 3):229-238.

94. 2011 Ashford JW, Adamson MM, Beale T, La D, Hernandez B, Noda A, Rosen A, O’Hara R, Fairchild JK, Spielman D, Yesavage JA. MR spectroscopy for assessment of memantine treatment in mild to moderate Alzheimer dementia. J Alzheimer’s Disease. 26(Sup 3):331-336.

95. 2011 Johnston JM, Greco SJ, Hamzelou A, Ashford JW, Tezapsidis N. Repositioning leptin as a therapy for Alzheimer's disease. Therapy. Sep;8(5):481-490.

96. 2012 Greco SJ, Hamzelou A, Johnston JM, Richardson S, Smith MA, Perry G, Ashford JW, Tezapsidis N. Isotyping the human TOMM40 variable-length polymorphism by gene amplification and restriction digest. Curr Alzheimer Res. 9(10):1168-73.

97. 2013 Ashford JW, Bayley PJ. Retrogenesis: a model of dementia progression in Alzheimer's disease related to neuroplasticity. J Alzheimers Dis. 33(4):1191-3.

98. 2013 Borson S, Frank L, Bayley PJ, Boustani M, Dean M, Lin PJ, McCarten JR, Morris JC, Salmon DP, Schmitt FA, Stefanacci RG, Mendiondo MS, Peschin S, Hall EJ, Fillit H, Ashford JW. Improving dementia care: the role of screening and detection of cognitive impairment. Alzheimers Dement. 9(2):151-9.

99. 2013 Trillo L, Das D, Hsieh W, Medina B, Moghadam S, Lin B, Dang V, Sanchez MM, De Miguel Z, Ashford JW, Salehi A. Ascending monoaminergic systems alterations in Alzheimer's disease; Translating basic science into clinical care. Neurosci Biobehav Rev. 37(8):1363-1379.

100. 2013 Lazzeroni LC, Halbauer JD, Ashford JW, Noda A, Hernandez B, Azor V, Hozack N, Hasson N, Henderson VW, Yesavage JA, Tinklenberg JR. Memantine is Associated with Longer Survival than Donepezil in a Veterans Affairs Prescription Database, 1997 to 2008. J Alzheimer’s Dis. 36(4):791-8.

101. 2013 Lange G, McAndrew L, Ashford JW, Reinhard M, Peterson M, Helmer DA. The War-Related Illness & Injury Study Center (WRIISC): A multidisciplinary translational approach to the care of Veterans with Chronic Multi Symptom Illness. Military Medicine. 178(7):705-7.

102. 2014 Johnston JM, Hu W, Fardo DW, Greco SJ, Perry G, Montine TJ, Trojanowski JQ, Shaw LM, Ashford JW, Tezapsidis N, For The Alzheimer's Disease Neuroimaging Initiative. Low Plasma Leptin in Mild Cognitively Impaired/Alzheimer's disease ADNI1 subjects- gender differences and diagnostic and therapeutic potential. Curr Alzheimer Res. 11(2):165-74

103. 2014 Bayley PJ, Kong JY, Helmer DA, Schneiderman A, Roselli LA, Rosse SM, Jackson JA, Baldwin J, Isaac L, Nolasco M, Blackman MR, Reinhard MJ, Ashford JW, Chapman JC; MIND Study Group. Challenges to be overcome using population-based sampling methods to recruit veterans for a study of post-traumatic stress disorder and traumatic brain injury. BMC Med Res Methodol. 14(1):48.

104. 2014 Dang V, Medina B, Das D, Moghadam S, Martin KJ, Lin B, Naik P, Patel D, Nosheny R, Ashford JW, Salehi A. Formoterol, a long-acting β2 adrenergic agonist, improves cognitive function and promotes dendritic complexity in a mouse model of Down syndrome. Biol Psychiatry. Feb 1;75(3):179-88.

105. 2014 Rosen AC, Ashford JW, Perry G. Ethics review as a catalyst for progress. J Alzheimer’s Dis. 40(2):233-5.

106. 2014 Adamson MM, Main K, Kong JY, Soman S, Furst A, Kinoshita K, Yesavage J, Ashford, JW. Integration of Clinical and Research Neuroimaging to Understand Traumatic Brain Injury in the Veteran Population. Fed Pract. 31(Suppl. June): 3S-7S.

107. 2014 Taylor JL, Scanlon BK, Farrell M, Hernandez B, Adamson MM, Ashford JW, Noda A, Murphy GM, Weiner MW. APOE-epsilon4 and aging of medial temporal lobe gray matter in healthy adults older than 50 years. Neurobiol Aging. Nov;35(11):2479-85.

108. 2014 Ashford JW, Furst AJ. Advancing brain imaging for Alzheimer's disease: integrating anatomic and physiologic measures. J Alzheimers Dis. 41(3):759-63

109. 2015 Bayley PJ, Kong JY, Mendiondo M, Lazzeroni LC, Borson S, Buschke H, Dean M, Fillit H, Frank L, Schmitt FA, Peschin S, Finkel S, Austen M, Steinberg C, Ashford JW. Findings from the National Memory Screening Day program. J Am Geriatr Soc. Feb;63(2):309-14.

110. 2015 Ashford JW, Mahoney L, Burkett T. A Role for Complementary and Integrative Medicine in Alzheimer's Disease Prevention. J Alzheimers Dis. 2015;48(1):13-4.

111. 2015 Tinklenberg JR, Kraemer HC, Yaffe K, O'Hara R, Ringman JM, Ashford JW, Yesavage JA, Taylor JL; California Alzheimer's Disease Centers. Donepezil treatment in ethnically diverse patients with Alzheimer disease. Am J Geriatr Psychiatry. Apr;23(4):384-90.

112. 2015 Isaac L, Main KL, Soman S, Gotlib IH, Furst AJ, Kinoshita LM, Fairchild JK, Yesavage JA, Ashford JW, Bayley PJ, Adamson MM. The impact of depression on Veterans with PTSD and traumatic brain injury: a diffusion tensor imaging study. Biol Psychol. Feb;105:20-8.

113. 2015 Ashford JW. Treatment of Alzheimer's Disease: The Legacy of the Cholinergic Hypothesis, Neuroplasticity, and Future Directions. J Alzheimers Dis. 47(1):149-56.

114. 2016 Salehi A, Ashford JW, Mufson EJ. Editorial: The Link between Alzheimer's Disease and Down Syndrome. A Historical Perspective. Curr Alzheimer Res. 13(1):2-6.

115. 2016 Sheng T, Fairchild JK, Kong JY, Kinoshita LM, Cheng JJ, Yesavage JA, Helmer DA, Reinhard MJ, Ashford JW, Adamson MM. The influence of physical and mental health symptoms on Veterans’ functional health status.J Rehabil Res Dev. 2016;53(6):781-796.

116. 2016 Durazzo TC, Korecka M, Trojanowski JQ, Weiner MW, O' Hara R, Ashford JW, Shaw LM; Alzheimer’s Disease Neuroimaging Initiative. Active Cigarette Smoking in Cognitively-Normal Elders and Probable Alzheimer's Disease is Associated with Elevated Cerebrospinal Fluid Oxidative Stress Biomarkers. J Alzheimers Dis. Jul 25;54(1):99-107.

117. 2016 Sun W, Lee S, Huang X, Liu S, Inayathullah M, Kim KM, Tang H, Ashford JW, Rajadas J. Attenuation of synaptic toxicity and MARK4/PAR1-mediated Tau phosphorylation by methylene blue for Alzheimer's disease treatment. Sci Rep. 2016 Oct 6;6:34784.

118. 2017 Waltzman D, Soman S, Hantke NC, Fairchild JK, Kinoshita LM, Wintermark M, Ashford JW, Yesavage J, Williams L, Adamson MM, Furst AJ. Altered Microstructural Caudate Integrity in Posttraumatic Stress Disorder but Not Traumatic Brain Injury. PLoS One. Jan 23;12(1).

119. 2017 Main KL, Soman S, Pestilli F, Furst A, Noda A, Hernandez B, Kong J, Cheng J, Fairchild JK, Taylor J, Yesavage J, Wesson Ashford J, Kraemer H, Adamson MM. DTI measures identify mild and moderate TBI cases among patients with complex health problems: A receiver operating characteristic analysis of U.S. veterans. Neuroimage Clin. 2017 Jun 24;16:1-16.

120. 2018 Smith CJ, Ashford W. APOE ε4 Allele-associated Alzheimer's disease risk is consistent with increased lifetime exposure to a neurotoxic process. J Systems Integr Neurosci. Jul 3(4):1-4.

121. 2018 McNerney MW, Sheng T, Nechvatal JM, Lee AG, Lyons DM, Soman S, Liao CP, O'Hara R, Hallmayer J, Taylor J, Ashford JW, Yesavage J, Adamson MM. Integration of neural and epigenetic contributions to posttraumatic stress symptoms: The role of hippocampal volume and glucocorticoid receptor gene methylation. PLoS One. 7;13(2):1-14.

122. 2018 Frank L, Ashford JW, Bayley PJ, Borson S, Buschke H, Cohen D, Cummings JL, Davies P, Dean M, Finkel SI, Hyer L, Perry G, Powers RE, Schmitt F. Genetic Risk of Alzheimer's Disease: Three Wishes Now That the Genie is Out of the Bottle. J Alzheimers Dis. 66(2):421-423.

123. 2019 van der Hoek MD, Nieuwenhuizen A, Keijer J, Ashford JW. The MemTrax Test Compared to the Montreal Cognitive Assessment Estimation of Mild Cognitive Impairment. J Alzheimers Dis. 67(3):1045-1054.

124. 2019 Ashford JW. Treatment of Alzheimer's Disease: Trazodone, Sleep, Serotonin, Norepinephrine, and Future Directions. J Alzheimers Dis. 67(3):923-930.

125. 2019 Ashford JW. The Dichotomy of Alzheimer's Disease Pathology: Amyloid-β and Tau. J Alzheimers Dis. 68(1):77-83.

126. 2019 Smith CJ, Ashford JW, Perfetti TA. Putative Survival Advantages in Young Apolipoprotein ɛ4 Carriers are Associated with Increased Neural Stress. J Alzheimers Dis. 68(3):885-923.

127. 2019 Cholerton B, Weiner MW, Nosheny RL, Poston KL, Mackin RS, Tian L, Ashford JW, Montine TJ. Cognitive Performance in Parkinson's Disease in the Brain Health Registry. J Alzheimers Dis. 68(3):1029-1038.

128. 2019 Ashford JW, Tarpin-Bernard F, Ashford CB, Ashford MT. A Computerized Continuous-Recognition Task for Measurement of Episodic Memory. J Alzheimers Dis. 69(2):385-399.

129. 2019 Bergeron MF, Landset S, Tarpin-Bernard F, Ashford CB, Khoshgoftaar TM, Ashford JW. Episodic-Memory Performance in Machine Learning Modeling for Predicting Cognitive Health Status Classification. J Alzheimers Dis. 70(1):373-381.

130. 2019 Zhou X, Ashford JW. Advances in screening instruments for Alzheimer's disease. Aging Med (Milton). 2(2):88-93.

131. 2019 Taylor JL, Hambro BC, Strossman ND, Bhatt P, Hernandez B, Ashford JW, Cheng JJ, Iv M, Adamson MM, Lazzeroni LC, McNerney MW. The effects of repetitive transcranial magnetic stimulation in older adults with mild cognitive impairment: a protocol for a randomized, controlled three-arm trial. BMC Neurol. 19(1):326.

132. 2020 Vakhtin AA, Zhang Y, Wintermark M, Massaband P, Robinson MT, Ashford JW, Furst AJ. White Matter Asymmetry: A Reflection of Pathology in Traumatic Brain Injury. J Neurotrauma. 37(2):373-381.

133. 2020 LaRocca MA, Ashford JW, Katz RB, Furst AJ. Military Environmental Exposure Concerns, Posttraumatic Stress Disorder, and Somatic Symptoms: Their Interrelation Among Treatment-Seeking Veterans. J Occup Environ Med. 62(1):74-79.

134. 2020 Zhang Y, Vakhtin AA, Jennings JS, Massaband P, Wintermark M, Craig PL, Ashford JW, Clark JD, Furst AJ. Diffusion tensor tractography of brainstem fibers and its application in pain. PLoS One. 15(2).

135. 2020 Bergeron MF, Landset S, Zhou X, Ding T, Khoshgoftaar TM, Zhao F, Du B, Chen X, Wang X, Zhong L, Liu X, Ashford JW. Utility of MemTrax and Machine Learning Modeling in Classification of Mild Cognitive Impairment. J Alzheimers Dis. 77(4):1545-1558.

136. 2020 Yamamoto V, Bolanos JF, Fiallos J, Strand SE, Morris K, Shahrokhinia S, Cushing TR, Hopp L, Tiwari A, Hariri R, Sokolov R, Wheeler C, Kaushik A, Elsayegh A, Eliashiv D, Hedrick R, Jafari B, Johnson JP, Khorsandi M, Gonzalez N, Balakhani G, Lahiri S, Ghavidel K, Amaya M, Kloor H, Hussain N, Huang E, Cormier J, Wesson Ashford J, Wang JC, Yaghobian S, Khorrami P, Shamloo B, Moon C, Shadi P, Kateb B. COVID-19: Review of a 21st Century Pandemic from Etiology to Neuro-psychiatric Implications. J Alzheimers Dis. 77(2):459-504.

137. 2020 Adamson MM, Main KL, Milazzo AC, Soman S, Kong J, Kolakowsky-Hayner S, Furst AJ, Ashford JW, Kang X. Cortical Thickness and Diffusion Properties in the Injured Brain: The Influence of Chronic Health Complaints. Mil Med. 185(Supplement\_1):168-175.

138. 2020 Zhang Y, Avery T, Vakhtin AA, Mathersul DC, Tranvinh E, Wintermark M, Massaband P, Ashford JW, Bayley PJ, Furst AJ. Brainstem atrophy in Gulf War Illness. Neurotoxicology. 78:71-79.

139. 2020 Ashford JW. INTREPAD: A randomized trial of naproxen to slow progress of presymptomatic Alzheimer disease (Reader response). Neurology. Mar 31;94(13):593-594.

140. 2020 Ashford JW, Tatem SB. Michelangelo's Sistine Chapel Frescoes: communications about the brain. Neurocase. Sep 4:1-6.

141. 2020 Bayley PJ, Schulz-Heik RJ, Cho R, Mathersul D, Collery L, Shankar K, Ashford JW, Jennings JS, Tang J, Wong MS, Avery TJ, Stanton MV, Meyer H, Friedman M, Kim S, Jo B, Younger J, Mathews B, Majmundar M, Mahoney L. Yoga is effective in treating symptoms of Gulf War illness: A randomized clinical trial. J Psychiatr Res. 11:S0022-3956(20)31083-9.

142. 2020 Gold JE, Baumgartl WH, Okyay RA, Licht WE, Fidel PL Jr, Noverr MC, Tilley LP, Hurley DJ, Rada B, Analysis of Measles-Mumps-Rubella (MMR) Titers of Recovered COVID-19 Patients. Ashford JW. mBio. 11(6),:e02628-20.

143. 2021 Ashford JW, Gold JE, Huenergardt MA, Katz RBA, Strand SE, Bolanos J, Wheeler CJ, Perry G, Smith CJ, Steinman L, Chen MY, Wang JC, Ashford CB, Roth WT, Cheng JJ, Chao S, Jennings J, Sipple D, Yamamoto V, Kateb B, Earnest DL. MMR Vaccination: A Potential Strategy to Reduce Severity and Mortality of COVID-19 Illness. Am J Med.;134(2):153-155.

144. 2021 Hantke N, Adamson MM, Noda A, Lazzeroni LC, Beaudreau SA, Yutsis M, Fairchild JK, Kinoshita LM, Kong J, Sheng T, Waltzman D, Ashford JW, Yesavage JA. Posttraumatic Stress Disorder-Associated Cognitive Deficits on the Repeatable Battery for the Assessment of Neuropsychological Status in a Veteran Population. Fed Pract. Jan;38(1):28-34.

145. 2021 Liu X, Chen X, Zhou X, Shang Y, Xu F, Zhang J, He J, Zhao F, Du B, Wang X, Zhang Q, Zhang W, Bergeron MF, Ding T, Ashford JW, Zhong L. Validity of the MemTrax Memory Test Compared to the Montreal Cognitive Assessment in the Detection of Mild Cognitive Impairment and Dementia due to Alzheimer's Disease in a Chinese Cohort. J Alzheimers Dis. 80(3):1257-1267.

146. 2021 Cheema AK, McNeil RB, Craddock T, Broderick G, Abreu MM, Aenlle K, Helmer DA, Ashford JW, Sullivan K, Bested A, Cohen DE, Shungu D, Chandler H, Fletcher MA, Krengel M, Klimas N. Gulf War Illness Clinical Trials and Interventions Consortium (GWICTIC): A collaborative research infrastructure for intervention and implementation. Life Sci. Aug 1;278:119636.

147. 2021 Zhang Y, Vakhtin AA, Dietch J, Jennings JS, Yesavage JA, Clark JD, Bayley PJ, Ashford JW, Furst AJ. Brainstem damage is associated with poorer sleep quality and increased pain in gulf war illness veterans. Life SciSep 1;280:119724.

148. 2021 Cheema AK, Wiener LE, McNeil RB, Abreu MM, Craddock T, Fletcher MA, Helmer DA, Ashford JW, Sullivan K, Klimas NG. A randomized phase II remote study to assess Bacopa for Gulf War Illness associated cognitive dysfunction: Design and methods of a national study. Life Sci. Oct 1;282:119819.

149. 2021 Xing G, Zhang Y, Zhang Y, Adamson MM, Furst AJ, Ashford JW. Editorial: Evidence-Based Anti-Inflammatory, Anti-Hypoperfusion and Anti-Anxiety/Insomnia Therapies Show Promises for TBI-Induced Post-Traumatic Symptoms and Cognitive Deficits: Advances in Diagnosis and Treatment of TBI-Induced Neurodegeneration and Cognitive Deficits. Front Neurol. Aug 11;12:695629.

150. 2021 Bayley PJ, Schulz-Heik RJ, Cho R, Mathersul D, Collery L, Shankar K, Ashford JW, Jennings JS, Tang J, Wong MS, Avery TJ, Stanton MV, Meyer H, Friedman M, Kim S, Jo B, Younger J, Mathews B, Majmundar M, Mahoney L. Yoga is effective in treating symptoms of Gulf War illness: A randomized clinical trial. J Psychiatr Res. Nov;143:563-571.

151. 2021 Vakhtin AA, Zhang Y, Wintermark M, Ashford JW, Furst AJ. Distant histories of mild traumatic brain injury exacerbate age-related differences in white matter properties. Neurobiol Aging. Nov;107:30-41.

152. 2021 Morris K, Nami M, Bolanos JF, Lobo MA, Sadri-Naini M, Fiallos J, Sanchez GE, Bustos T, Chintam N, Amaya M, Strand SE, Mayuku-Dore A, Sakibova I, Biso GMN, DeFilippis A, Bravo D, Tarhan N, Claussen C, Mercado A, Braun S, Yuge L, Okabe S, Taghizadeh-Hesary F, Kotliar K, Sadowsky C, Chandra PS, Tripathi M, Katsaros V, Mehling B, Noroozian M, Abbasioun K, Amirjamshidi A, Hossein-Zadeh GA, Naraghi F, Barzegar M, Asadi-Pooya AA, Sahab-Negah S, Sadeghian S, Fahnestock M, Dilbaz N, Hussain N, Mari Z, Thatcher RW, Sipple D, Sidhu K, Chopra D, Costa F, Spena G, Berger T, Zelinsky D, Wheeler CJ, Ashford JW, Schulte R, Nezami MA, Kloor H, Filler A, Eliashiv DS, Sinha D, DeSalles AAF, Sadanand V, Suchkov S, Green K, Metin B, Hariri R, Cormier J, Yamamoto V, Kateb B. Neuroscience20 (BRAIN20, SPINE20, and MENTAL20) Health Initiative: A Global Consortium Addressing the Human and Economic Burden of Brain, Spine, and Mental Disorders Through Neurotech Innovations and Policies. J Alzheimers Dis. 83(4):1563-1601.

153. 2022 Nami M, Thatcher R, Kashou N, Lopes D, Lobo M, Bolanos JF, Morris K, Sadri M, Bustos T, Sanchez GE, Mohd-Yusof A, Fiallos J, Dye J, Guo X, Peatfield N, Asiryan M, Mayuku-Dore A, Krakauskaite S, Soler EP, Cramer SC, Besio WG, Berenyi A, Tripathi M, Hagedorn D, Ingemanson M, Gombosev M, Liker M, Salimpour Y, Mortazavi M, Braverman E, Prichep LS, Chopra D, Eliashiv DS, Hariri R, Tiwari A, Green K, Cormier J, Hussain N, Tarhan N, Sipple D, Roy M, Yu JS, Filler A, Chen M, Wheeler C, Ashford JW, Blum K, Zelinsky D, Yamamoto V, Kateb B. A Proposed Brain-, Spine-, and Mental- Health Screening Methodology (NEUROSCREEN) for Healthcare Systems: Position of the Society for Brain Mapping and Therapeutics. J Alzheimers Dis. 86(1):21-42.

154. 2022 Cheng J, Fairchild JK, McNerney MW, Noda A, Ashford JW, Suppes T, Chao SZ, Taylor J, Rosen AC, Durazzo TC, Lazzeroni LC, Yesavage J. Repetitive Transcranial Magnetic Stimulation as a Treatment for Veterans with Cognitive Impairment and Multiple Comorbidities. J Alzheimers Dis. 85(4):1593-1600.

155. 2022 Ashford JW, Schmitt FA, Bergeron MF, Bayley PJ, Clifford JO, Xu Q, Liu X, Zhou X, Kumar V, Buschke H, Dean M, Finkel SI, Hyer L, Perry G. Now is the Time to Improve Cognitive Screening and Assessment for Clinical and Research Advancement. J Alzheimers Dis. 87(1):305-315.

156. 2022 Rosen AC, Arias JJ, Ashford JW, Blacker D, Chhatwal JP, Chin NA, Clark L, Denny SS, Goldman JS, Gleason CE, Grill JD, Heidebrink JL, Henderson VW, Lavacot JA, Lingler JH, Menon M, Nosheny RL, Oliveira FF, Parker MW, Rahman-Filipiak A, Revoori A, Rumbaugh MC, Sanchez DL, Schindler SE, Schwarz CG, Toy L, Tyrone J, Walter S, Wang LS, Wijsman EM, Zallen DT, Aggarwal NT. The Advisory Group on Risk Evidence Education for Dementia: Multidisciplinary and Open to All. J Alzheimers Dis. 90(3):953-962. doi: 10.3233/JAD-220458. PubMed PMID: 35938255; PubMed Central PMCID: PMC9901285.

157. 2022 Cohen DE, Sullivan KA, McNeil RB; Gulf War Illness Common Data Elements Working Group:; Symptoms Assessment Working Group:; McNeil RB, Ashford W, Bested A, Bunker J, Cheema A, Cohen DE, Cook D, Cournoyer J, Craddock T, Golier J, Hardie A, Helmer D, Lindheimer JB, Lloyd PJ, Kerr K, Krengel M, Nadkarni S, Nugent S, Paris B, Reinhard M, Rumm P, Schneiderman A, Sims KJ, Steele L, Turner M; Systems Assessment Working Group:; Sullivan KA, Abdullah L, Abreu M, Abu-Donia M, Aenlle K, Arocho J, Balbin E, Baraniuk J, Block K, Block M, DeBeer B, Engdahl B, Filipov N, Fletcher MA, Kalasinsky V, Kokkotou E, Lidie K, Little D, Loging W, Morris M, Nathanson L, Nichols MD, Pasinetti G, Shungu D, Waziry P, VanLeeuwen J, Younger J. A common language for Gulf War Illness (GWI) research studies: GWI common data elements. Life Sci. 2022 Feb 1;290:119818. doi: 10.1016/j.lfs.2021.119818. Epub 2021 Aug 2.

PMID: 34352259

158. 2022 Ashford JW, Clifford JO, Anand S, Bergeron MF, Ashford CB, Bayley PJ. Correctness and response time distributions in the MemTrax continuous recognition task: Analysis of strategies and a reverse-exponential model. Front Aging Neurosci. 2022;14:1005298. doi: 10.3389/fnagi.1005298. eCollection. PubMed PMID: 36437986; PubMed Central PMCID: PMC9682919.

159. 2022 Ashford JW, Tatem SB. Michelangelo's Presentations in the Sistine Chapel: Brain Evolution and the Relationship of the Brain to Specific Cognitive Functions. Neuroscientist. Nov 19;:10738584221136091. doi: 10.1177/10738584221136091. PubMed PMID: 36408533

160. 2023 Chen W, Lin C, Su F, Fang Y, Liu G, Chen YC, Zhou X, Yao X, Ashford CB, Li F, Ashford JW, Fu QL, Pei Z. Early Diagnosis of Mild Cognitive Impairment due to Alzheimer's Disease Using a Composite of MemTrax and Blood Biomarkers. J Alzheimers Dis. 94(3):1093-1103. doi: 10.3233/JAD-230182. PubMed PMID: 37355900.

161. 2023 Smith CJ, Ashford JW. Apolipoprotein ɛ4-Associated Protection Against Pediatric Enteric Infections Is a Survival Advantage in Pre-Industrial Populations. J Alzheimers Dis. 93(3):907-918. doi: 10.3233/JAD-221218. PubMed PMID: 37125551.

162. 2023 Ashford JW, Clifford JO, Bergeron MF. Advancing screening for cognitive impairment: the MemTrax continuous recognition test. Aging (Albany NY). 2023 Jun 14;15(12):5230-5231. doi: 10.18632/aging.204828. PubMed PMID: 37319322; PubMed Central PMCID: PMC10333071.

163. 2023 Zhao X, Dai S, Zhang R, Chen X, Zhao M, Bergeron MF, Zhou X, Zhang J, Zhong L, Ashford JW, Liu X. Using MemTrax memory test to screen for post-stroke cognitive impairment after ischemic stroke: a cross-sectional study. Front Hum Neurosci. 2023;17:1195220. doi: 10.3389/fnhum. 1195220. eCollection 2023. PubMed PMID: 37529406; PubMed Central PMCID: PMC10387538.

164. 2023 Ashford JW. Neuroplasticity: The Critical Issue for Alzheimer's Disease and Links to Obesity and Depression. Am J Geriatr Psychiatry. 2023 Oct;31(10):867-875. doi: 10.1016/j.jagp.2023.07.007. Epub Jul 15. PubMed PMID: 37481402.

165. 2023 Blum K, Ashford JW, Kateb B, Sipple D, Braverman E, Dennen CA, Baron D, Badgaiyan R, Elman I, Cadet JL, Thanos PK, Hanna C, Bowirrat A, Modestino EJ, Yamamoto V, Gupta A, McLaughlin T, Makale M, Gold MS. Dopaminergic dysfunction: Role for genetic & epigenetic testing in the new psychiatry. J Neurol Sci. 2023 Oct 15;453:120809. doi: 10.1016/j.jns.2023.120809. PubMed PMID: 37774561.

166. 2024 Liu W, Yu L, Deng Q, Li Y, Lu P, Yang J, Chen F, Li F, Zhou X, Bergeron MF, Ashford JW, Xu Q. Toward digitally screening and profiling AD: A GAMLSS approach of MemTrax in China. Alzheimers Dement. Aug 31;. doi: 10.1002/alz.13430. [Epub ahead of print] PubMed PMID: 37654085.

167. 2024 Smith CJ, Perfetti TA, Chokshi C, Venugopal C, Ashford JW, Singh SK. Risk factors for glioblastoma are shared by other brain tumor types.Hum Exp Toxicol. Jan-Dec;43:9603271241241796. doi: 10.1177/09603271241241796. PMID: 38520250.

168. 2024 Zhang Y, Moore M, Jennings JS, Clark JD, Bayley PJ, Ashford JW, Furst AJ.

The role of the brainstem in sleep disturbances and chronic pain of Gulf War and Iraq/Afghanistan veterans. Front Mol Neurosci. Jan 8;16:1266408. doi: 10.3389/fnmol.2023.1266408. eCollection 2023. PMID: 38260809.

169. 2024 Liu Y, Wu L, Chen W, Su F, Liu G, Zhou X, Ashford CB, Li F, Ashford JW, Pei Z, Xian W. The MemTrax memory test for detecting and assessing cognitive impairment in Parkinson's disease. Parkinsonism Relat Disord. 2024 Mar;120:106016. doi: 10.1016/j.parkreldis.2024.106016. Feb 1. PMID: 38325255

**PUBLICATIONS (peer-reviewed journals), MULTI-SITE PARTICIPATING SCIENTIST**

2010 – 2023: 56 publications listed on PubMed for “Ashford W” referencing participation in ADNI (Alzheimer’s Disease Neuroimaging Initiative), the ADCS (Alzheimer’s Disease Cooperative Study), the Citalopram Treatment for Alzheimer’s Disease Study (CitAD), Gulf War Illness Common Data Elements Working Group: Symptoms Assessment Working Group.

**EDITED BOOKS**

Book Series: Advances in Alzheimer’s Disease

Series Editors:

George Perry, PhD, University of Texas at San Antonio, USA

J. Wesson Ashford, MD, PhD, Stanford / VA Aging Clinical Research Center, USA

Paula Moreira, PhD, University of Coimbra, Portugal

Editor Emeritus: Mark A. Smith†, PhD, Case Western Reserve University, USA

Aims and Scope: Advances in Alzheimer's Disease brings together the latest insights in Alzheimer’s disease research in specific areas in which major advances have been made. This book series assembles and builds on work recently published in the Journal of Alzheimer's Disease (JAD) and also includes further contributions to ensure comprehensive coverage of the topic. The emphasis is on the development of novel approaches to understanding and treating Alzheimer’s and related diseases.

Volume 1: Handbook of Animal Models in Alzheimer’s Disease (2011)

Volume 2: Handbook of Imaging the Alzheimer Brain (2011) (Ashford et al., Editors)

Volume 3: Alzheimer’s Disease: Advances for a New Century (2013)

Volume 4: Handbook of Depression in Alzheimer’s Disease (2015)

Volume 5: Handbook of Infection and Alzheimer’s Disease (2017)

Volume 6: Alzheimer’s Disease: New Beginnings (2018)

Volume 7: Handbook of Traumatic Brain Injury and Neurodegenerative Disease (2020)

Volume 8: Handbook of Alzheimer’s Disease and Air Pollution (2021)

Volume 9: Handbook of Microbiome and Gut-Brain-Axis in Alzheimer’s Disease (2022)

Volume 10: Handbook of Alzheimer Prevention (I) and Intervention (II) (in press) (Raji, Ashford, et al., Editors)

Volume 2: Ashford JW, Rosen A, Adamson M, Bayley P, Sabri O, Furst A, Black SE, Weiner M (Eds.) Handbook of Imaging the Alzheimer Brain. IOS Press, Amsterdam. 2011

**BOOK CHAPTERS**

1. 1988 Ashford, J.W. and Bice, J.L. Choice reaction time in aged rhesus monkeys as a model of AD. In: Becker, R.E., Giacobini (eds) Advances in Alzheimer Therapy. Taylor-Francis, New York. 87-94

2. 1988 Kumar, V., Murphy, J., Sherman, K.A., Ashford, J.W. and Markwell, S.J. Cognitive and neuroendocrine changes with physostigmine in Alzheimer's disease patients. In: Becker, R.E., Giacobini (eds) Advances in Alzheimer Therapy. Taylor-Francis, New York. 163-171

3. 1988 Sherman, K.A., Kumar, V., Ashford, J.W., Murphy, J.W., Elble, R.J. and Giacobini, E. Effect of oral physostigmine in senile dementia patients: utility of blood cholinesterase inhibition and neuroendocrine responses to define pharmacokinetics and pharmacodynamics. In: Strong, R. et al, Central Nervous System Disorders of Aging: Clinical Intervention and Research. Raven Press, New York. 71-90

4. 1989 Coburn, K.L., Ashford, J.W. and Moreno, M.A. VEP latency changes in Alzheimer's disease. In: Raz, I. (ed.) Neurological and Psychiatric Applications of Topographic Brain Mapping of EGG and Evoked Potentials. Bio-Logic, Chicago.

5. 1993 Ashford, J.W. and Zec, R.F. Pharmacological Treatment in Alzheimer's Disease. In: Parks, R.W. and Zec, R.F. and Wilson, R.S. Neuropsychology of Alzheimer's Disease and Other Dementias. Oxford University Press.

6. 1996 Ashford, J.W., Schmitt, F.A., Wermeling, D., Bieber, F., Orazem, J., and Gulanski, B. Advantages of the "Time-Index" Method for Measurement of Alzheimer Dementia: Assessment of Metrifonate Benefit. In: Becker, R. and Giacobini, E. (Eds.) Alzheimer Disease: From Molecular Biology to Therapy. Birkhauser: Boston.

7. 1996 Schmitt, F.A., Ashford, J.W., Ferris, S., Mackell, J., Saxton, J., Schneider, L., Clark, C., Ernesto, C., Schafer, K., and Thal, L. Severe Impairment Battery: A Potential Measure for AD Clinical Trials. In: Becker, R. and Giacobini, E. (Eds.) Alzheimer Disease: From Molecular Biology to Therapy. Birkhauser: Boston.

8. 1998 Ashford, J.W., Mattson, M., Kumar, V. Neurobiological Systems Disrupted. In: Kumar, V. and Eisdorfer, C. (Eds.) Advances in the Diagnosis and Treatment of Alzheimer's Disease. Springer Publishing Company: New York, pp: 53-89.

9. 1998 Ashford, J.W., Schmitt, F., Kumar, V. Diagnosis of Alzheimer's Disease. In: Kumar, V. and Eisdorfer, C. (Eds.) Advances in the Diagnosis and Treatment of Alzheimer's Disease. Springer Publishing Company: New York, pp: 111-151.

10. 1998 Ashford, J.W., Coburn, K.L., Fuster, J.M. Functional Cognitive Networks in Primates. In: Parks, R.W. and Levine, D.S. Fundamentals of Neural Networks: Neuropsychology and Cognitive Neuroscience. The MIT Press: Cambridge, Mass, pp: 33-60.

11. 2008 Gallagher-Thompson, D., Lonergan, K.H., Holland, J., China, D., Ashford, J.W. Supporting Family Caregivers. In: Lipton AM, Weiner MF, editors. American Psychiatric Publishing Textbook of Alzheimer's Disease and Other Dementias: The App Textbook of Geriatric Psychiatry Diagnostic Issues in Dementia. Arlington, VA: American Psychiatric Publishing; pp:353-366.

12. 2011 Ashford JW, Salehi A, Furst A, Bayley P. Imaging the Alzheimer Brain: The Pathology and Pathophysiological Bases of Alzheimer’s Disease: Implications for Advancing Diagnostic Imaging. In: Ashford JW, Rosen A, Adamson M, Bayley P, Sabri O, Furst A, Black SE, Weiner M (Eds.) Handbook of Imaging the Alzheimer Brain. IOS Press, Amsterdam. Pages 3-10.

13. 2011 Ashford JW, Coburn KL, Rose TL, Bayley PJ. The topography of P300 energy loss in aging and Alzheimer’s disease. In: Ashford JW, Rosen A, Adamson M, Bayley P, Sabri O, Furst A, Black SE, Weiner M (Eds.) Handbook of Imaging the Alzheimer Brain. IOS Press, Amsterdam. Pages 435-444.

14. 2011 Ashford JW, Adamson MM, Beale T, La D, Hernandez B, Noda A, Rosen A, O’Hara R, Fairchild JK, Spielman D, Yesavage JA. Spectroscopy for assessment of memantine treatment in mild to moderate Alzheimer dementia In: Ashford JW, Rosen A, Adamson M, Bayley P, Sabri O, Furst A, Black SE, Weiner M (Eds.) Handbook of Imaging the Alzheimer Brain. IOS Press, Amsterdam. Pages 599-604.

15. 2014 Johnston JM, Perry G, Ashford JW, Tezapsidis N. Leptin in Alzheimer’s Disease and Other Cognitive Disorders and Association with Underlying Lipid Abnormalities. In: Blum EL. Leptin: Biosynthesis, Functions and Clinical Significance. Nova Science Publishers, Inc., Hauppauge, NY. Pages 1 – 15.

16. 2019 Ashford JW, Schmitt FA, Smith CJ, Kumar V, Askari N. Assessment of Cognitive Impairment, Alzheimer’s Disease, and Other Forms of Dementia. In: Yeo G, Gerdner L, Gallagher-Thompson D. Ethnicity and the Dementia, Third Edition. Routledge, Taylor & Francis Group, NY. Pages 41 – 68.

**NATIONAL COURSES / ORGANIZED SYMPOSIUMS**

1. 1998 Kumar, V., Ashford, J. W., Krasuski, J. Advances in Diagnosis and Management of Alzheimer's Disease in Psychiatric Practice. American Psychiatric Association Annual Meeting, Toronto, Canada.

2. 2001 Ashford, J. W., Walsh, J., Farlow, M., Murphy, G., Gallagher-Thompson, D., Coon, D. Apolipoprotein-E (APO-E) genotype in predicting Alzheimer's disease. American Association of Geriatric Psychiatry, San Francisco.

3. 2002 Ashford, J.W. Neurological and Medical Aspects - Critical Elements in Geriatric Psychiatry (Geriatric Psychiatry Board Review Course, invited faculty). American Association of Geriatric Psychiatry. Orlando

4. 2003 Ashford, J.W. (organizer), Schmitt, F.A., Borson, S, Buschke, H., Dash, P., Mendiondo, M, Kraemer, H. Designing brief Alzheimer screening tests for use in general medical practice. American Association of Geriatric Psychiatry, Honolulu (symposium, 5/3).

5. 2003 Raskind, M., Ashford, J.W. (organizer) Schmitt, F.A., Crane, P., van Belle, G., Geldmacher, D. Measuring cognitive dysfunction in Alzheimer's disease. American Association of Geriatric Psychiatry, Honolulu (symposium, 5/4).

6. 2003 Ashford, JW (organizer), Schmitt, F, Borson, S, Buschke, H, Mendiondo, M, Tornatore JB, Kraemer HC. Diverse approaches to Alzheimer screening. American Psychiatry Association, San Francisco (symposium, 5/20).

7. 2003 Ashford, JW (organizer), Schmitt, F. (co-chair), Borson, S, Buschke, H., Brodaty, H. Developing approaches to Alzheimer Screening. International Psychogeriatric Association, Chicago (symposium, 8/19).

8. 2005 Ashford, JW, Tornatore, J (organizers) Alzheimer’s Association

9. 2005 O’Hara, R, Ashford, JW (organizers) Dementia screening. International Psychogeriatric Association

10. 2007 O’Hara, R, Ashford, JW (organizers) Dementia Screening. American Association for Geriatric Psychiatric Annual meeting, New Orleans.

11. 2008 Ashford (organizer); JW, Frank, L; Borson, Soo; Steffens, D. Dementia Screening in Clinical and Community Settings. American Association for Geriatric Psychiatric Annual meeting, Orlando, FL.

12. 2009 – 2013 – numerous – not logged.

13. 2008 – 2023 – numerous presentations, Webinars, professional communications organized in role as Director of the California site of the War Related Illness and Injury Study Center for the Veteran’s Affairs Department of Public Health

PUBLISHED ABSTRACTS AND INTERNATIONAL / NATIONAL PRESENTATIONS

1. 1979 Blumenthal, M.D. and Ashford, J.W. et al. Psychogeriatric Services: transcontinental views. American Psychiatric Association, Annual Meeting, Chicago, IL.

2. 1980 Strauss, G.D., Yager, J., Liston, E., Ashford, J.W., Gales, M., and Strauss, G.E. Testing psychiatric knowledge with in-house exams. American Psychiatric Association, Annual Meeting, San Francisco, CA.

3. 1980 Schulte, J.L., and Ashford, J.W. et al. Mentally ill offender: Treatment issues in California. American Psychiatric Association, Annual Meeting, San Francisco, CA.

4. 1980 Fuster, J.M., Willey, T.J., Riley, D.M. and Ashford, J.W. Alcohol effects on Neuroelectric activity and behavior of monkeys in a cognitive task. Society for Neuroscience: Tenth Annual Meeting.

5. 1983 Ashford, J.W., and Fuster, J.M. Occipital and inferotemporal response to photic stimuli in the monkey performing a cognitive task. Society for Neuroscience: Thirteenth Annual Meeting, Boston, MA.

6. 1985 Kuhl, D.E. Metter, E.J., Benson, D.F. and Ashford, J.W., et al. Similarities of cerebral glucose metabolism in Alzheimer's and Parkinsonian dementia, Brain Conference, Sweden.

7. 1985 Kuhl, D.E., Metter, J., Benson, D.F., Ashford, J.W., Riege, W.H., Fujikawa, D.G., Markham, C.H., Mazziotta, J.C., Maltese, A. and Dorsey, D.A. Similarities of cerebral glucose metabolism in Alzheimer's and Parkinsonian dementia: Journal of Cerebral Blood Fl. Met. 5.

8. 1985 Ashford, J.W., Rosenblatt, M.J., Bekian, C. and Hayes, T. Complications in the complete dementia evaluation: complications and complexities, American Psychiatric Association Annual Meeting, Washington, D.C.

9. 1986 Ashford, J.W., Moffitt, T.E., and Bekian, C. Dementia staging: utility of MMS and ADL scales. Midwest Neurobiology Meeting, Springfield, IL.

10. 1986 Ashford, J.W., Sherman, K.A., Elble, R.J., Jess, J., Larson, L.S., Rey, P., Higgins, C., Best, S., Woodruff, E.M. and Mcllhany, M. Physostigmine effect on human memory and plasma cholinesterase. Midwest Neurobiology Meeting, Springfield, IL.

11. 1986 Sherman, K.A., Ashford, J.W., Elble, R.J., Hess, J. and Kumar, V. Effect of oral physostigmine in senile dementia patients. Fifth Annual Symposium on Geriatrics and Gerontology, St. Louis.

12. 1986 Ashford, J.W., Elble, R., Sherman, K., Hess, J., Best, S. and Higgins, C. Physostigmine: memory vs plasma cholinesterase. American Psychiatric Association Annual Meeting, Washington, D.C.

13. 1986 Sherman, K.A., Ashford, J.W., Elble, R.J., Hess, J., Mcllhany, Kumar, V., Becker, R.E., Giacobini, E. Inhibition of blood cholinesterase after oral physostigmine in Alzheimer patients. Society of Neuroscience.

14. 1986 Sherman, K.A., Elble, R.J. Ashford, J.W., and Hess, J. Predicting response to physostigmine in senile dementia patients: inhibition of plasma or red blood cell cholinesterase. American Geriatric Society 43rd Annual Meeting, Chicago, IL.

15. 1986 Ashford, J.W., Hsu, L.N., Becker, M., Kumar, V. and Bekian, C. Mini mental status and activities of daily living: cross validation by scalogram and item analysis techniques. Gerontological Society of America, The Gerontologist, Chicago, IL.

16. 1987 Sherman, K.A., Kumar, V., Ashford, J.W. and Murphy, J. Neuroendocrine response to physostigmine in senile dementia patients, Midwest Neurobiology Meeting, Springfield, IL.

17. 1987 Giacobini, E., Ashford, J.W., Becker, R.E., Elble, R.J. and Sherman, K.A. Are there cholinergic markers for Alzheimer's disease? Winter Conference on Brain Res, Vail, CO.

18. 1987 Ashford, J.W., Becker, R., and Dettling, R. Frontal system dementia in late schizophrenia. American Psychiatric Association, Annual Meeting.

19. 1987 Small, G., Kuhl, D.E., Riege, W.H., Ashford, J.W. and Fujikawa, D.G. Diagnosis of Alzheimer subtypes with PET scan, American Psychiatric Association, Annual Meeting.

20. 1987 Ashford, J.W. Physostigmine treatment of Alzheimer patients' memory vs. plasma cholinesterase. International Psychogeriatric Association, Third Congress, Chicago, IL.

21. 1987 Small, G., Kuhl, D., Riege, W., Fujikawa, D., Ashford, W, Metter, J. and Mazziotta, J. Local cerebral metabolic differences in subgroups of Alzheimer disease. International Psychogeriatric Association, Third Congress, Chicago, IL.

22. 1987 Kuhl, D.E., Small, G.W., Riege, W.H., Fujikawa, D.G., Metter, E.J., Benson, D.F., Ashford, J.W., Mazziotta, J.C., Maltese, A. and Dorsey, D.A. Cerebral metabolic patterns before the diagnosis of probable Alzheimer's disease. 13th International Symposium on Cerebral Blood Flow and Metabolism, Montreal, Canada.

23. 1987 Kuhl, D.E., Small, G.W., Riege, W.H., Fujikawa, D.G., Metter, E.J., Benson, D.F., Ashford, J.W., Mazziotta, J.C., Maltese, A. and Dorsey, D.A. Cerebral metabolic patterns before the diagnosis of probable Alzheimer's disease. 13th International Symposium on Cerebral Blood Flow and Metabolism. Toronto, Canada.

24. 1987 Ashford, J.W., Kumar, V., Becker, M., Barringer, M. and Vicari, S. Measuring Alzheimer progression: increasing precision using MMS-Ex: ADL's; CDR-M. Geriatric Society of America, Annual Meeting, Washington, D.C. The Gerontologist.

25. 1987 Ashford, J.W. and Bice, J. Scopolamine effect on choice reaction time in the monkey. Society for Neuroscience, Annual Meeting.

26. 1987 Woodward, S.H., Brown, W.S., Marsh, J.T., Ashford, J.W., Winter, J. and Larue, A. P300 and CT-scan: their combined efficacy in dementia diagnosis. Gerontological Society of American, Annual Meeting, Washington, D.C. The Gerontologist.

27. 1987 Kumar, V., Ashford, J.W. and Bekian, C. Measuring depression in Alzheimer patients. Gerontological Society of America, Annual Meeting, Washington, D.C. The Gerontologist.

28. 1987 Kuhl, D.E., Small, G.W., Riege, W.H., Fujikawa, D.G., Metter, E.J., Benson, D.F., Ashford, J.W., Mazziotta, J.C., Maltese, A. and Dorsey, D.A. Abnormal PET-FDG scans in early Alzheimer's disease. Journal of Nuclear Medicine.

29. 1988 Ashford, J.W., Kumar, V., Becker, M., Barringer, M. and Vicari, S. Measuring Alzheimer Progression: increasing precision using MMS-Ex: ADL's;CDR-M. Governor's Conference on Long Term Care, Chicago, IL.

30. 1988 Ashford, J.W. and Bice, J. Choice reaction time in aged rhesus monkeys as a model of AD. Presented at an International Conference: Advances in Alzheimer's Therapy, Springfield, IL.

31 cholinergic cell loss. Presented at an International Conference: Advances in Alzheimer Therapy, Springfield, IL.

32. 1988 Maroun, L.E., Yao, X., Ryan, N. and Ashford, J.W. Can RFLP analysis discriminate between familial and sporadic Alzheimer's disease? Presented at an International Conference: Advance in Alzheimer Therapy, Springfield, IL.

33. 1989 Prohaska, T., Ashford, W., Brody, J., Eisdorfer, C., Gorelich, P., Hirschfeld, R., Levy, P., Luchins, P., Paveza, G., Trozzolo, T. and Cohen, P. Concomitant presenting problems of dementia at time of diagnosis. XIV International Congress of Gerontology, Acapulco, Mexico.

34. 1989 Paveza, J., Ashford, W., Brody, J., Eisdorfer, C., Gorelich, P., Hirschfeld, R., Levy, P., Lew, R., Luchins, D., Prohaska, T. and Cohen, D. Demographic characteristics of dementia patients from a three-state registry and its implications for community care. XIV International Congress of Gerontology, Acapulco, Mexico.

35. 1989 Bice, J., Edwards, H. and Ashford, J.W. Reaction time changes with aging in the monkey. Society for Neuroscience, Phoenix, AZ.

36. 1989 Ashford, W., Bice, J., Vicari, S. and Feldman, E. Simple choice reaction vs Alzheimer severity. Gerontology Society of American, Minneapolis, MN.

37. 1989 Cohen, P., Ashford, J.W., Gorelich, P., Eisdorfer, C., Luchins, D., Paveza, G., Hirschman, R., Levy, P. and Brody, J. A large scale prototype Alzheimer's disease patient registry. Gerontological Society of America, Minneapolis, MN.

38. 1989 Coburn, K.L., Parks, R.W. and Ashford, J.W. The P300 in dementia: divergent physiological and behavioral changes. National Academy of Neuropsychologist.

39. 1989 Parks, R.W., Coburn, K.L., Zec, R.F., Ashford, J.W., Moreno, M.A., Vicari, S., Feldman, S. and Dodrill, K. Electrocortical mapping in Alzheimer's disease with vascular lesions. International Neuropsychological Society.

40. 1989 Brewer, G.J., Domino, L. and Ashford, J.W. Alzheimer-like pathology induced by human serum in cultured hippocampal neurons. Society for Neuroscience, Phoenix, AZ.

41. 1989 Bice, J., Edwards, H. and Ashford, J.W. Reaction time changes with aging in the monkey. Society for Neuroscience, Phoenix, AZ.

42. 1990 Ashford, J.W., Rashid, A., Lawrence, D., Calache, M., Bice, J., Evans, G. and Anderson, D. AD Pathology: quantitation by MRI? Society for Neuroscience, St. Louis, MO.

43. 1990 Coburn, K.L. and Ashford, J.W. Visual evoked potential components in dementia: selective delay of flash P2 in probable Alzheimer's disease, 6th International Conference of Alzheimer Disease International, Mexico City, Mexico.

44. 1990 Brewer, G.J., Miksanek, B.K. and Ashford, J.W. Quantitative immunoreactivity of Alzheimer-like antigens increased by elderly human serum treatment of cultured neurons. Society for Neuroscience, St. Louis, MO.

45. 1990 Paveza, G.J., Cohen, D., Ashford, W., Brody, J., Eisdorfer, C., Hirschman, R., Luchins, D., Shaw, H. and Trozzolo, T. The developing of a peripheral marker for the diagnosis of Alzheimer's disease, 6th International Conference of Alzheimer Disease International, Mexico City, Mexico.

46. 1990 Cohen, D., Paveza, G., Eisdorfer, C., Gorelich, P., Luchins, D., Hirschman, R. and Ashford, W. Morbidity and co-morbidity in patients with Alzheimer's disease (AD): results from a large-scale patient registry, 6th International Conference of Alzheimer Disease International, Mexico City, Mexico.

47. 1990 Cohen, D., Paveza, G., Eisdorfer, C., Gorelich, P., Luchines, D., Hirschman, R. and Ashford W. The developing of a peripheral marker for the diagnosis of Alzheimer's disease, 6th International Conference of Alzheimer Disease International, Mexico City, Mexico.

48. 1990 Cohen, D., Paveza, G., Eisdorfer, C., Gorelich, P., Luchins, D., Hirschman, R. and Ashford, W. Morbidity and co-morbidity in patients with Alzheimer's disease (AD): results from a large-scale patient registry, Gerontological Society of America, Boston, MA.

49. 1990 Eisdorfer, C., Cohen, D, Ashford, W., Luchins, D., Paveza, G., Brody, J., Hirschman, R. and Gorelich, P. An empirical challenge to the validity of the global deterioration scale to stage Alzheimer's disease, Gerontological Society of America, Boston, MA, The Gerontologist, 30, #138, pp. 156a.

50. 1990 Paveza, G.J., Cohen, D., Ashford, W., Brody, J., Eisdorfer, C., Hirschman, R., Luchins, D., Shaw, H. and Trozzolo, T. Violence in families with an Alzheimer patient, Gerontological Society of America, Boston, MA, the Gerontologist, 30, #122, pp. 147a.

51. 1991 Ashford, J.W., Edwards, H. Memory in the monkey: an automated paradigm and the effect of nicotine. Society for Neuroscience, New Orleans, LA.

52. 1991 Coburn, K.L., Ashford, J.W., Moreno, M.A. Delayed late component of visual global field power in probable Alzheimer's disease. Society for Neuroscience, New Orleans, LA.

53. 1992 Coburn, K.L. and Ashford, J.W. Delayed late VEP component in Alzheimer's disease. International Society for Brain Electromagnetic Topography, 3rd International Congress, Amsterdam, Netherlands.

54. 1992 Coburn, K.L., Ashford, J.W., Zec, R.F. Uses of brain electrical activity mapping in the detection of Alzheimer's disease in the presence of vascular lesions. KNAW, EBBS workshop on Functioning Brain Imaging, Amsterdam, Netherlands.

55. 1992 Ashford, J.W., Coburn, V.L., Yamashita, K. P300 Power Loss in Aging and Alzheimer's Disease. Society for Neuroscience, #306.20, Anaheim, CA.

56. 1993 Mattson, M.P., Cheng, B., Goodman, Y., Smith-Swintosky, V.L., Ashford, J.W., Oeltgen, J. Mimicking the neuroprotective mechanism of growth factor action with low molecular weight agents. Society for Neuroscience, Washington, D.C.

57. 1993 Mark, R., Ashford, J.W., Goodman, Y., and Mattson, M.P. Valproic Acid Attenuates Excitotoxicity and Neurofibrillary Tangle-like Antigenic Changes in Hippocampal Neurons. Society for Neuroscience, Washington, D.C.

58 1994 Ashford, J.W., Shan, M., Butler, S., Rajesekar, A., Schmitt, F.A. Temporal quantification of Alzheimer's disease severity. Fourth International Conference on Alzheimer's Disease and Related Disorders, Minneapolis, Minnesota.

59. 1994 Pettigrew, L.C., Smith, C.D., Schmitt, F.A., Wermeling, D., Tikhtman, A.J., Doshi, N., Ashford, J.W., and Gulanski, B. Cerebral energy metabolism and cognitive performance in Alzheimer's disease. American Association of Neurology.

60 1994 Ashford, J.W. Non-pharmacological treatment of Alzheimer's disease patients. American Psychiatric Association, Philadelphia, PA.

61. 1996 Ashford, J.W. Advantages of the "Time-Index" Method for Measurement of Alzheimer Dementia: Assessment of Metrifonate Benefit. Fourth International Nice/Springfield Symposium on Advances in Alzhemier Therapy, Nice, France.

62. 1996 Schmitt, F.A., Ashford, J.W., Ferris, S., Mackell, J., Saxton, J., Schneider, L., Clark, C., Ernesto, C., Schafer and Thal, L. Severe Impairment Battery: A Potential Measure for AD Clinical Trials. Fourth International Nice/Springfield Symposium on Advances in Alzhemier Therapy, Nice, France.

63. 1996 Tekirian, T.L., Snowdon, D.A., Racke D., Riley, K.P., Davis, D.G., Ashford, J.W., Soultanian, N.S., Markesbery, W.R., and Geddes, J.W. Entorhinal Cortex Pathology and Cognitive Performance in Aging and Alzheimer's Disease: Findings from the Nun Study. Society for Neurosciences, Washington, D.C.

64. 1996 Dutton, K., Pace, S., Cook, C., Sickman, J., Fowler, J., Ashford, J.W., and Sebastian, J. "Advanced Practice Nurse Management for Chronically Ill Older Veterans". Third International Conference on Long Term Care Case Manainging, "Bridging the Many Worlds of Case Management", American Society on Aging in San Diego, CA. .

65. 1997 Ashford, J.W.,Shih, W.J., Coupal, J., Shetty, R., Schneider, A., Cool, C., Stipp, V., Aleem, A., and Schmitt, F.A. "Brain Spect Versus Dementia Severity in Alzhimer's Disease. 1997 Annual Meeting Society for Neuroscience, New Orleans, Louisiana.

66. 1997 Shih, W.J., Ashford, J.W., Stipp, V., Magoun, S.L., Coupal, J.J., Gross, K.K. Consecutive Brain SPECT Surface Three Dimensional Displays Show Progression of Cerebral Cortical Abnormalities in Alzheimer's Disease. American Association of Physicists in Medicine, Chicago, Illinois.

67. 1997 Coupal, J.J., Shih, W.J., Ashford, J.W. Refrigerated-Saline Reconstitution of Freeze-Dried ECD: An Easy First Step for Long-Term Storage of ECD Solution. American Association of Physicists in Medicine, Chicago, Illinois.

68. 1998 Mendiondo, M.S., Ashford, J.W., Kryscio, R.J., Schmitt, F.A. Modeling mini-mental state exam changes in Alzheimer's disease. Statistics in Alzheimer's Disease. Lexington, Kentucky.

69. 1998 Ashford, J.W., Shih, W.-J., Mendiondo, M., Stipp, V., Coupal, J.J., Aleem, A., Aleem, B., Schmitt, F.A. Alzheimer's disease and SPECT: 3-dimensional brain surface displays (BSD's) reflect dementia severity, while consecutive studies show progression of individual abnormalities. Annual Meeting, Society for Neuroscience, Los Angeles, CA.

70. 1999 Ashford, J.W., Shih, W.-J. Gulf War veterans with cortical perfusion defects on 3-D SPECT: A series of 10 cases. 1999 Annual Meeting, Society for Neuroscience, Miami, FL.

71. 2000 Ashford, J.W., Reisberg, B., Yesavage, J., Stern, Y., Mungas, D., Modeling longitudinal changes and time factors in Alzheimer's disease: Technology to improve patient evaluation and treatment. 13th Annual Meeting, American Association for Geriatric Psychiatry, Miami, FL.

72. 2000 Shih, W.-J., Ashford, J.W. Cerebral cortical perfusion abnormalities on brain SPECT in Gulf War veterans. 2000 Annual Meeting of the American Roentgen Ray Society, Washington, D.C.

73. 2001 Ashford, J.W., Mendiondo, M.S., Kryscio, R.J., Schmitt, F.A. A Minute Alzheimer Screen. International Psychogeriatrics Association Meeting, Nice, France.

74. 2002 Ashford, J.W., Mendiondo, M.S., Kryscio, R.J., Schmitt, F.A. Designing a Brief Alzheimer Screen, American Association of Geriatric Psychiatry, Orlando, FL.

75. 2002 Ashford, J.W., Mendiondo, M.S., Kryscio, R.J., Schmitt, F.A. Designing a Brief Alzheimer Screen. Statistics In Alzheimer's Disease. Lexington, KY

76. 2002 Ashford, J.W., Kindy, M., Shih, W.-J., Cool, C., Aleem, B., Cobb, L., Tsanatos, D. Age of onset of Alzheimer’s disease is earlier in patients with an APOE  allele. Annual Meeting, Society for Neuroscience, Orlando, Fl

77. 2003 Goldstein L, Ashford JW, Busciglio J, Crutcher K, Gouras G, Kinoshita J, Mandelkow E, Sudol M. Live discussion. From here to there: AbetaPP as an axonal transport receptor--how could this explain neurodegeneration in AD. 15 July 2002. Journal of Alzheimers Disease. 2003 Dec;5(6):483-9.

78. 2003 Xiong, S., Xie1, C., Lovell, M.A.1,3; Markesbery, W.R., Ashford, J.W., Gallicchio, V.S. Lithium inhibits GSK-3 mediated hyperphosphorylation of tau in the hippocampus of starved mice. Annual Meeting, Society for Neuroscience, New Orleans, LA. Nov. 12, #840.24.

79. 2004 – present: numerous presentations not logged

LOCAL/STATE PRESENTATIONS

80. 1991 "The Temporal Lobe and Perception of Psychic Trauma." 17th Annual Mid-winter Program in Contuing Medical Education for Psychiatrists. Lake Tahoe, CA.

81. 1993 "Alzheimer's Disease: Can Anticonvulsants Stop the Pathology?" Kentucky Psychiatric Association, Covington, KY.

82. 1994 "Assessing the Mental Status of the Elderly Patient," the 25th Family Medicine and Primary Care Review, University of Kentucky, Lexington, KY.

83. 1996 Tekirian, T.L., Snowdon, D.A., Racke D., Riley, K.P., Davis, D.G., Ashford, J.W., Soultanian, N.S., Markesbery, W.R., and Geddes, J.W. Entorhinal Cortex Pathology and Cognitive Performance in Aging and Alzheimer's Disease: Findings From the Nun Study. Sanders-Brown Alzheimer's Disease Research Center & Department of Anatomy and Neurobiology, Lexington, Kentucky.

84. 2001 "Advances in Alzheimer's Disease" University of Louisville, Symposium on Advances in Psychopharmacology, in conjunction with the Kentucky Psychiatric Association meeting (invited).

85. 2002 Alzheimer's Disease. (keynote address) Kentucky Psych Assoc, Annual Meeting.

2003 – present: numerous presentations, not logged

2011 – present: numerous WEBINARs for WRIISC program: [www.warrelatedillness.va.gov](http://www.warrelatedillness.va.gov)